Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells

Sheng Dai, Shu Yang, Xin Hu, Wei Sun, Gregory Tawa, Wenge Zhu, Aaron D. Schimmer, Chao He, Bingliang Fang, Hongbo Zhu, Wei Zheng

Mol Cancer Ther (2019) 18 (7): 1265–1277.

https://doi.org/10.1158/1535-7163.MCT-18-1241

Published: 01 July 2019

View articletitled, 17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells

Includes: Supplementary data

Journal Articles

Abstract A299: Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells.

Dannie Bernard, Marinella Gebbia, Swayam Prabha, Marcela Gronda, Neil MacLean, Xiaoming Wang, Rose Hurren, Mahadeo A. Sukhai, Eunice E. Cho, Morris F. Manolson, Alessandro Datti, Jeffrey Wrana, Rima Al-Awar, Ahmed Aman, Corey Nislow, Guri Giaever, Aaron D. Schimmer

Mol Cancer Ther (2013) 12 (11_Supplement): A299.

https://doi.org/10.1158/1535-7163.TARG-13-A299

Published: 01 November 2013

View articletitled, Abstract A299: Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells.

Journal Articles

Abstract A125: Silencing Stat3 signaling in human cancers: Identifying potent small molecule inhibitors of Stat3 function.

Brent D. G. Page, Xialoei Zhang, Jennifer Atkinson, Zhi Hua Li, Aaron D. Schimmer, Suzanne Trudel, James Turkson, Patrick T. Gunning

Mol Cancer Ther (2011) 10 (11_Supplement): A125.

https://doi.org/10.1158/1535-7163.TARG-11-A125

Published: 12 November 2011

View articletitled, Abstract A125: Silencing Stat3 signaling in human cancers: Identifying potent small molecule inhibitors of Stat3 function.

Journal Articles

Abstract A121: Direct SH2 domain-targeting inhibitors of Stat3: Potent anticancer agents and mitigators of drug resistance.

Brent D. G. Page, Jennifer Atkinson, Yoong Lim Wong, Sina Haftchenary, Paul A. Spagnuolo, Ira L. Kraft, Thomas O'Hare, James Turkson, Michael W. Deininger, Aaron D. Schimmer, Patrick T. Gunning

Mol Cancer Ther (2011) 10 (11_Supplement): A121.

https://doi.org/10.1158/1535-7163.TARG-11-A121

Published: 12 November 2011

View articletitled, Abstract A121: Direct SH2 domain-targeting inhibitors of Stat3: Potent anticancer agents and mitigators of drug resistance.

Journal Articles

Abstract A22: A genome-wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance.

Craig D. Simpson, Rose Hurren, Neil MacLean, Yanina Eberhard, Troy Ketela, Jason Moffat, Aaron D. Schimmer

Mol Cancer Ther (2011) 10 (11_Supplement): A22.

https://doi.org/10.1158/1535-7163.TARG-11-A22

Published: 12 November 2011

View articletitled, Abstract A22: A genome-wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance.

Journal Articles

Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands

Tabitha E. Wood, Shadi Dalili, Craig D. Simpson, Mahadeo A. Sukhai, Rose Hurren, Kika Anyiwe, Xinliang Mao, Fernando Suarez Saiz, Marcela Gronda, Yanina Eberhard, Neil MacLean, Troy Ketela, John C. Reed, Jason Moffat, Mark D. Minden, Robert A. Batey, Aaron D. Schimmer

Mol Cancer Ther (2010) 9 (1): 246–256.

https://doi.org/10.1158/1535-7163.MCT-09-0495

Published: 12 January 2010

View articletitled, Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands

Includes: Supplementary data

Journal Articles

Abstract A51: Identification of compounds targeting human leukemia stem cells

Sean P. McDermott, Kolja Eppert, Aaron D. Schimmer, Yanina Eberhard, John E. Dick

Mol Cancer Ther (2009) 8 (12_Supplement): A51.

https://doi.org/10.1158/1535-7163.TARG-09-A51

Published: 10 December 2009

View articletitled, Abstract A51: Identification of compounds targeting human leukemia stem cells

Journal Articles

Abstract A106: A phase 1 study of ENMD‐2076 in patients with relapsed or refractory acute myeloid leukemia (AML)

Karen W. Yee, Joseph Brandwein, Mark D. Minden, Deborah Sanfelice, Sue Chow, David W. Hedley, Aaron D. Schimmer, Andre C. Schuh, Vikas Gupta, Carolyn F. Sidor, Jamie Arnott, Graham Fletcher, Mark Bray, Hsiao‐Wei Tina Chen

Mol Cancer Ther (2009) 8 (12_Supplement): A106.

https://doi.org/10.1158/1535-7163.TARG-09-A106

Published: 10 December 2009

View articletitled, Abstract A106: A phase 1 study of ENMD‐2076 in patients with relapsed or refractory acute myeloid leukemia (AML)

Journal Articles

A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death

Tabitha E. Wood, Shadi Dalili, Craig D. Simpson, Rose Hurren, Xinliang Mao, Fernando Suarez Saiz, Marcela Gronda, Yanina Eberhard, Mark D. Minden, Philip J. Bilan, Amira Klip, Robert A. Batey, Aaron D. Schimmer

Mol Cancer Ther (2008) 7 (11): 3546–3555.

https://doi.org/10.1158/1535-7163.MCT-08-0569

Published: 11 November 2008

View articletitled, A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death

Journal Articles

Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy

Hong Chang, Aaron D. Schimmer

Mol Cancer Ther (2007) 6 (1): 24–30.

https://doi.org/10.1158/1535-7163.MCT-06-0443

Published: 19 January 2007

View articletitled, Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy

Journal Articles

The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice

Nhu-An Pham, James W. Jacobberger, Aaron D. Schimmer, Pinjiang Cao, Marcella Gronda, David W. Hedley

Mol Cancer Ther (2004) 3 (10): 1239–1248.

https://doi.org/10.1158/1535-7163.1239.3.10

Published: 14 October 2004

View articletitled, The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells

Abstract A299: Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells.

Abstract A125: Silencing Stat3 signaling in human cancers: Identifying potent small molecule inhibitors of Stat3 function.

Abstract A121: Direct SH2 domain-targeting inhibitors of Stat3: Potent anticancer agents and mitigators of drug resistance.

Abstract A22: A genome-wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance.

Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands

Abstract A51: Identification of compounds targeting human leukemia stem cells

Abstract A106: A phase 1 study of ENMD‐2076 in patients with relapsed or refractory acute myeloid leukemia (AML)

A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death

Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy

The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only